Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00496860 | Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies | PHASE1 | COMPLETED | 26 | — | — | May 1, 2007 | Oct 1, 2009 | Jul 22, 2013 | 4 | United States |
Number of serious adverse events per cohort
Number of dose limiting toxicities (DLTs). A DLT is a toxicity that results in patient withdrawal from the study as defined in the protocol.
| Name | Type | Description |
|---|---|---|
| ALT-801 | BIOLOGICAL | Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles. |
ENTRY CRITERIA: DISEASE CHARACTERISTICS: * Locally advanced or metastatic malignancies * Histologically or cytologically confirmed * Evaluable * Surgically and medically incurable * Not responding to standard therapy or no other standard therapy exists * Human leukocyte antigen (HLA)-A2.1/p53 posi...